Edition:
United Kingdom

Cardinal Health Inc (CAH.N)

CAH.N on New York Stock Exchange

55.12USD
3:53pm BST
Change (% chg)

$-0.05 (-0.09%)
Prev Close
$55.17
Open
$55.16
Day's High
$55.36
Day's Low
$54.73
Volume
494,690
Avg. Vol
765,244
52-wk High
$75.74
52-wk Low
$48.15

Latest Key Developments (Source: Significant Developments)

Cardinal Health Reports Q3 Non-GAAP Earnings Per Share $1.39
Thursday, 3 May 2018 

May 3 (Reuters) - Cardinal Health Inc ::CARDINAL HEALTH REPORTS THIRD-QUARTER RESULTS FOR FISCAL YEAR 2018.Q3 NON-GAAP EARNINGS PER SHARE $1.39.Q3 GAAP EARNINGS PER SHARE $0.81.Q3 REVENUE $33.6 BILLION VERSUS I/B/E/S VIEW $33.45 BILLION.Q3 EARNINGS PER SHARE VIEW $1.51 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 NON-GAAP EARNINGS PER SHARE $4.85 TO $4.95.UPDATES FISCAL YEAR 2018 OUTLOOK..THIRD-QUARTER REVENUE FOR PHARMACEUTICAL SEGMENT INCREASED 5 PERCENT TO $29.7 BILLION.  Full Article

Cordis And Medinol Announce FDA Approval Of EluNIR Drug-Eluting Stent System
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Cardinal Health Inc ::CORDIS AND MEDINOL ANNOUNCE FDA APPROVAL OF THE INNOVATIVE ELUNIR DRUG-ELUTING STENT SYSTEM.  Full Article

Shanghai Pharmaceuticals' unit‍ signs deal to acquire Cardinal in Malaysia
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Says its unit‍ Century Global signs deal to acquire Cardinal Malaysia for about $557 million.  Full Article

Cardinal Health says shareholders re-elected all 11 members to board in preliminary voting ​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Cardinal Health Inc :Cardinal Health - ‍based on preliminary results of shareholder voting at co's annual meeting, shareholders re-elected all 11 members to board​.  Full Article

Cardinal Health Inc outlines leadership succession plan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cardinal Health Inc :Cardinal Health Inc outlines leadership succession plan.Cardinal Health Inc - ‍Jorge Gomez, CFO of Cardinal Health's medical segment, to succeed Kaufmann as chief financial officer​.Cardinal Health Inc - ‍Mike Kaufmann named chief executive officer, effective January 1, 2018​.Cardinal Health Inc - ‍George Barrett continues as executive chairman of board through november 2018 annual meeting of shareholders​.Cardinal Health Inc - ‍Kaufmann will succeed George Barrett​.Cardinal Health Inc - ‍Gregory Kenny, Cardinal Health's lead independent director, will assume role of non-executive chairman​.  Full Article

Cardinal Health reports Q1 GAAP earnings per share $0.36
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cardinal Health Inc :Cardinal Health Inc reports first-quarter results for fiscal year 2018.Reaffirms fy 2018 non-GAAP earnings per share view $4.85 to $5.10.Q1 revenue $32.6 billion versus I/B/E/S view $33.48 billion.Q1 GAAP earnings per share $0.36.Q1 earnings per share view $1.00 -- Thomson Reuters I/B/E/S.Cardinal Health Inc - ‍first-quarter revenue for pharmaceutical segment increased 1 percent to $28.9 billion​.Fy2018 earnings per share view $4.95 -- Thomson Reuters I/B/E/S.Cardinal Health Inc - qtrly ‍non-GAAP diluted EPS $1.09​.  Full Article

Galena Biopharma says co and Cardinal Health entered into a settlement relating to product swap agreement​
Wednesday, 18 Oct 2017 

Oct 19 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc says on October 12, co and Cardinal Health entered into a settlement relating to product swap agreement​ - SEC filing.Galena Biopharma Inc - ‍pursuant to agreement , co, Cardinal agreed to resolve all of their outstanding disputes over a product swap agreement​.Galena Biopharma Inc - ‍Cardinal will destroy all of zuplenz oral soluble film that is returned as a result of product swap agreement.Galena Biopharma Inc - ‍product swap agreement with Cardinal will be terminated as of effective date of agreement​.  Full Article

Shanghai Pharmaceuticals submits bids for U.S. drug distributor Cardinal Health's China business
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Says it has submitted bids for U.S. drug distributor Cardinal Health's <<>> China business.  Full Article

Cardinal Health - ‍Expects to incur estimated exit or disposal activities costs of $130 mln
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - Cardinal Health Inc :Cardinal Health - ‍expects to incur estimated costs associated with exit or disposal activities of $130 million on a pre-tax basis.Cardinal Health - ‍expected costs related with restructuring include $125 million in contract termination costs related to existing third-party arrangement.Cardinal Health Inc - $125 million of costs were incurred in 3 months ended Sept 30, remaining costs expected to be incurred in FY ending June 30, 2018.Cardinal Health-entered deal with third-party distributor to effect transition of distribution of medical unit's surgeon gloves in some countries outside U.S..  Full Article

Cardinal Health Q4 non-GAAP earnings per share $1.31
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Cardinal Health Inc :Cardinal Health reports Q4 and fiscal 2017 results, provides 2018 guidance.Q4 non-GAAP earnings per share $1.31.Q4 GAAP earnings per share $0.86.Q4 revenue $33 billion versus I/B/E/S view $32.73 billion.Q4 earnings per share view $1.24 -- Thomson Reuters I/B/E/S.Sees FY 2018 non-GAAP earnings per share $4.85 to $5.10 from continuing operations.Sees FY 2019 non-GAAP earnings per share at least $5.60.Reports Q4 non-GAAP earnings per share $1.31.FY 2017 GAAP earnings per share $4.03.Reports FY 2017 revenue of $130 billion.Reports Q4 revenue up 5 percent.Fourth-quarter revenue for pharmaceutical segment increased 5 percent to $29.6 billion.Q4 revenue view $32.73 billion -- Thomson Reuters I/B/E/S.FY2018 earnings per share view $5.27 -- Thomson Reuters I/B/E/S.Says taking some discrete actions, which will affect its EPS in FY18 and will improve co's trajectory for 2019 and beyond.Says it is targeting fiscal 2019 non-GAAP EPS of at least $5.60.  Full Article

Photo

Express Scripts staking out million dollar gene therapies

Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.